Trials / Available
AvailableNCT06810141
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ImmunityBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- —
Summary
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are ineligible to participate in a clinical trial using rMBCG, or for other reasons cannot participate (eg, geographically unable to access a study site).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | rMBCG | 1-19.2e8 colony-forming units (CFU) of rMBCG |
Timeline
- First posted
- 2025-02-05
- Last updated
- 2026-03-27
Locations
62 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06810141. Inclusion in this directory is not an endorsement.